H.I.G. Portfolio Company Royo Group Combines with Fiora Bath Collections
31.1.2018 20:27:00 EET | Business Wire | Press release
H.I.G. Capital (“H.I.G.”), a leading global private investment firm with more than €20 billion of equity capital under management, announced today that its portfolio company, Royo Group (“Royo”) has completed the integration of Fiora Bath Collections (“Fiora”) as part of its growth strategy.
Headquartered in Nájera (La Rioja, Spain), Fiora was established in 1986, and is Europe’s leading manufacturer of resin shower trays, a rapidly growing product category. Its success has been driven by innovation in the design of new bathroom materials. Resin is highly versatile and offers excellent performance. It also has the ability to imitate the look and feel of very different material types, offering consumers an infinite range of bathroom design and decoration options. Fiora´s products are available in more than 30 countries worldwide. Fiora’s current shareholders will remain as shareholders in Royo and will remain involved in their current roles, playing a leadership management role in the combined business.
The combination of Fiora and Royo is part of Royo’s strategy to grow in other geographic markets and segments, to broaden its leadership to other product categories and to continue improving customer service. The objective of the co-operation between H.I.G. and Royo Group – and now with Fiora – is to create the leading independent player in the European bathroom sector.
Royo and Fiora’s sales networks will continue to operate separately, but will benefit from joint purchasing savings and other shared services.
Jaime Bergel, Managing Director, H.I.G. Europe, said: “Fiora has been a pioneering manufacturer of resin shower trays and is largely responsible for the runaway success of this new product throughout Europe, especially in the South. Fiora’s clients are attracted by the high quality of its products, its innovative design, as well as the exceptional pre-sale and post-sale support, factors that have positioned the company as the undisputed global leader in its market. The integration of Fiora with Royo will allow the Group to continue developing its R&D activity, international expansion and growth. The company will also benefit from becoming part of an international leading specialist in bathroom furnishings.”
Raúl Royo, CEO Royo said: “The integration of Fiora is a major corporate milestone in our ONE 2020 strategy. It strengthens our position as the European market leader and complements our channel and brand strategy that we began to roll out some years ago, a strategy that has been key to our considerable growth in Europe. The integration also heralds our move into a new product category – shower trays and panels –, allowing us to offer a wide range of shower and bath furnishing solutions. Our aim is to become the preeminent player in the European bathroom sector in the next few years.”
José Barrio, one of the Fiora founders stated: “The entire Fiora team is both delighted and enthusiastic at the prospect of being part of Royo’s growth strategy supported by H.I.G., while retaining our identity, team and premium brand image. The complementary nature of our products and markets will enable us to bolster the growth already seen over the past decade and strengthen our competitive position. We are certain our employees, suppliers and sales network will support us on this new venture.”
About Fiora
Headquartered in Nájera (La Rioja, Spain), Fiora is Europe’s leading manufacturer of resin shower trays. The company also makes and distributes resin panels, bathroom furnishings, radiators and accessories. Fiora was established in the 1980s and was owned by its four founding partners until its integration into the Royo Group. Its success has been built on innovation in the design of new bathroom materials, such as resins. Fiora’s primary facilities are located at Nájera in La Rioja, Spain, where manufacturing is set to continue. The facilities span a total of 26,000 square metres and are equipped with cutting-edge technology. For more information, please refer to the Fiora website: www.fiora.es
About Royo
The Royo Group has its roots in the partnership established among various members of the Royo family, the original founders and owners of the business with a track record dating back 45 years. The group aims to strengthen its position in the European market for bathroom products and to step up its internationalisation plans to become the leading independent player in the European bathroom sector. RGIB currently has factories in Spain, Poland and Mexico, as well as sales operations in the United States and India. The company operates in over 60 countries on 5 continents.
Royo is the only Valencia-based company – and one of just a handful in Spain – to be invited to join Smart Eureka, a cluster of smart European 4.0 companies. Being asked to join the Smart Eureka initiative is one of the main milestones in RGIB’s new expansion phase until 2020. The Spanish Government, through the Ministry of Industry, recently added the group to its “Cre100do” programme, an initiative launched by foreign trade body ICEX, Bankinter and the Círculo de Empresarios that aims to help 100 Spanish companies grow to become large businesses over the next 5 years. For more information, please refer to the RG website: www.royogroup.com
About H.I.G. Capital
H.I.G. is a leading global private equity and alternative assets investment firm with over €20 billion of equity capital under management*. Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Mexico City and Rio de Janeiro, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:
1. H.I.G.’s. equity funds invest in management buyouts, recapitalisations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
3. H.I.G.’s real assets funds invest in value-added properties, which can benefit from improved asset management practices.
Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of €28 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.
H.I.G. European Capital Partners Spain is a legally independent advisor to H.I.G. Capital LLC, H.I.G. Europe Capital Partners, L.P. and H.I.G. Europe Capital Partners II, L.P.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180131005985/en/
Contact information
H.I.G. Capital
Jaime Bergel, P +34 91 737 50 50, F +34 91 737 50 49
Managing
Director
jbergel@higcapital.com
www.higcapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
